Articles: sepsis.
-
Randomized Controlled Trial
Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
The addition of molgramostim (recombinant human granulocyte-macrophage colony-stimulating factor) to antibiotic therapy for nontraumatic and generalized abdominal sepsis is effective and has a significant impact on length of hospitalization, direct medical costs, and mortality. ⋯ Addition of molgramostim to antibiotic therapy reduces the rate of infectious complications, the length of hospitalization, and costs in patients with nontraumatic abdominal sepsis.
-
Zhongguo Zhong Xi Yi Jie He Za Zhi · Feb 2006
Randomized Controlled Trial[Effects of raw rhubarb on plasma D-lactate and procalcitonin expressions in patients with sepsis].
To investigate the effects of raw rhubarb (RR) on levels of plasma D-lactate and procalcitonin in patients with sepsis. ⋯ RR could ameliorate the intestinal permeability and reduce the shifting of intestinal bacteria, so as to ease the condition of disease in patients with sepsis.
-
Int. J. Infect. Dis. · Jan 2006
Randomized Controlled Trial Clinical TrialDecreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.
Acute septicemic melioidosis is associated with systemic release of endotoxin and the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin-1, and interleukin-6. Excessive release of these cytokines may lead to endothelial injury, depletion of naturally occurring endothelial modulators, microvascular thrombosis, organ failure, and death. ⋯ The inflammatory response to systemic Burkholderia pseudomallei infection leads to depletion of the natural endothelial modulators protein C, protein S, and antithrombin. Both baseline and continued deficiency of these endothelial modulators is predictive of poor outcome in melioidosis.
-
J. Thromb. Haemost. · Jan 2006
Randomized Controlled Trial Multicenter StudyTreatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
Disseminated intravascular coagulation (DIC) is a serious complication of sepsis that is associated with a high mortality. ⋯ High-dose AT without concomitant heparin in septic patients with DIC may result in a significant mortality reduction. The adapted ISTH DIC score may identify patients with severe sepsis who potentially benefit from high-dose AT treatment.
-
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue · Dec 2005
Randomized Controlled Trial[Clinical study of low molecular weight heparin therapy for sepsis].
To investigate the therapeutic effect of low molecular weight heparin (LMWH) therapy on sepsis. ⋯ LMWH can ameliorate sepsis by down-regulating the levels of pro-inflammatory cytokines, and suppressing the release of oxygen-derived free radicals. It is a promising treatment measure in sepsis patient with safety and no severe side effects.